XML 27 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2024
Mar. 20, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Trading Symbol LRMR    
Entity Registrant Name LARIMAR THERAPEUTICS, INC.    
Entity Central Index Key 0001374690    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Common Stock, Shares Outstanding   64,027,892  
Entity Current Reporting Status Yes    
Entity Shell Company false    
Entity File Number 001-36510    
Entity Tax Identification Number 20-3857670    
Entity Address, Address Line One Three Bala Plaza East    
Entity Address, Address Line Two Suite 506    
Entity Address, City or Town Bala Cynwyd    
Entity Address, State or Province PA    
Entity Address, Postal Zip Code 19004    
City Area Code 844    
Local Phone Number 511-9056    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Security Exchange Name NASDAQ    
Entity Interactive Data Current Yes    
Document Annual Report true    
Document Transition Report false    
Entity Incorporation State Country Code DE    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Public Float     $ 313,608,353
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction false    
Documents Incorporated by Reference Part III of this Annual Report on Form 10-K incorporates certain information by reference from the registrant’s definitive proxy statement for the 2025 annual meeting of stockholders to be filed no later than 120 days after the end of the registrant’s fiscal year ended December 31, 2024.    
Auditor Firm ID 238    
Auditor Name PricewaterhouseCoopers LLP    
Auditor Location Philadelphia, Pennsylvania, USA    
Auditor Opinion

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Larimar Therapeutics, Inc. and its subsidiary (the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations and comprehensive loss, of changes in stockholders’ equity and of cash flows for the years then ended, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.